These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 33941568)

  • 1. Development of BRAF V600E Mutation in NRAS Q61L Mutated Rectal Cancer.
    Cao MN; Chen KT; Li QF; Wang L; Jin GW; Na RT; Ma J; Liu YT; Gao JL
    Ann Clin Lab Sci; 2021 Mar; 51(2):262-266. PubMed ID: 33941568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRAF(V600E) and NRAS(Q61L/Q61R) mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting.
    Kakavand H; Walker E; Lum T; Wilmott JS; Selinger CI; Smith E; Saw RP; Yu B; Cooper WA; Long GV; O'Toole SA; Scolyer RA
    Histopathology; 2016 Oct; 69(4):680-6. PubMed ID: 27151331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concurrent NRAS-BRAF variants in metastatic colorectal cancer: a Tunisian case report.
    Douik H; Sahraoui G; Jemaà M; Doghri R; Charfi L; Mrad K
    Anticancer Drugs; 2024 Jun; 35(5):462-465. PubMed ID: 38451831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patients.
    Sclafani F; Wilson SH; Cunningham D; Gonzalez De Castro D; Kalaitzaki E; Begum R; Wotherspoon A; Capdevila J; Glimelius B; Roselló S; Thomas J; Tait D; Brown G; Oates J; Chau I
    Int J Cancer; 2020 Jan; 146(1):94-102. PubMed ID: 31199501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NRAS (Q61R), BRAF (V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas.
    Uguen A; Talagas M; Costa S; Samaison L; Paule L; Alavi Z; De Braekeleer M; Le Marechal C; Marcorelles P
    Diagn Pathol; 2015 Jul; 10():121. PubMed ID: 26204954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study.
    Palomba G; Doneddu V; Cossu A; Paliogiannis P; Manca A; Casula M; Colombino M; Lanzillo A; Defraia E; Pazzola A; Sanna G; Putzu C; Ortu S; Scartozzi M; Ionta MT; Baldino G; Sarobba G; Capelli F; Sedda T; Virdis L; Barca M; Gramignano G; Budroni M; Tanda F; Palmieri G
    J Transl Med; 2016 Oct; 14(1):292. PubMed ID: 27737711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of BRAF, NRAS, KRAS mutations as markers for the detection of papillary thyroid cancer from FNAB specimens by pyrosequencing analysis.
    Park SJ; Sun JY; Hong K; Kwak JY; Kim EK; Chung WY; Choi JR
    Clin Chem Lab Med; 2013 Aug; 51(8):1673-80. PubMed ID: 23585181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study.
    Guren TK; Thomsen M; Kure EH; Sorbye H; Glimelius B; Pfeiffer P; Österlund P; Sigurdsson F; Lothe IMB; Dalsgaard AM; Skovlund E; Christoffersen T; Tveit KM
    Br J Cancer; 2017 May; 116(10):1271-1278. PubMed ID: 28399112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAF, NRAS, and GNAQ Mutations in Conjunctival Melanocytic Nevi.
    Francis JH; Grossniklaus HE; Habib LA; Marr B; Abramson DH; Busam KJ
    Invest Ophthalmol Vis Sci; 2018 Jan; 59(1):117-121. PubMed ID: 29332123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rare case of triple mutant (KRAS + NRAS + BRAF) metastatic colon adenocarcinoma.
    Vittal A; Sharma D; Samanta I; Kasi A
    BMJ Case Rep; 2019 Sep; 12(9):. PubMed ID: 31519714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China.
    Huang M; Yan C; Xiao J; Wang T; Ling R
    Diagn Pathol; 2019 Jul; 14(1):74. PubMed ID: 31300059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MEK Inhibition Reverses Aberrant Signaling in Melanoma Cells through Reorganization of NRas and BRAF in Self Nanoclusters.
    Yakovian O; Sajman J; Arafeh R; Neve-Oz Y; Alon M; Samuels Y; Sherman E
    Cancer Res; 2021 Mar; 81(5):1279-1292. PubMed ID: 33355187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Coexistence of RAS and BRAF Mutations in Metastatic Colorectal Cancer: A Case Report and Systematic Literature Review.
    Afrăsânie VA; Gafton B; Marinca MV; Alexa-Stratulat T; Miron L; Rusu C; Ivanov AV; Balan GG; Croitoru AE
    J Gastrointestin Liver Dis; 2020 Jun; 29(2):251-256. PubMed ID: 32530992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative analysis of BRAF, NRAS and c-KIT mutation status between tumor tissues and autologous tumor cell-lines of stage III/IV melanoma.
    Knol AC; Pandolfino MC; Vallée A; Nguyen F; Lella V; Khammari A; Denis M; Puaux AL; Dréno B
    Exp Dermatol; 2015 Jan; 24(1):70-3. PubMed ID: 25363723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
    Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
    Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter Evaluation of the Idylla NRAS-BRAF Mutation Test in Metastatic Colorectal Cancer.
    Prieto-Potin I; Montagut C; Bellosillo B; Evans M; Smith M; Melchior L; Reiltin W; Bennett M; Pennati V; Castiglione F; Bürrig KF; Cooper U; Dockhorn-Dworniczak B; Rossenbach C; Luna-Aguirre CM; Barrera-Saldaña HA; Machado JC; Costa JL; Yacobi R; Tabibian-Keissar H; Buglioni S; Ronchetti L; Douglas-Berger L; Dubbink HJ; Alorini M; Sabourin JC; Rojo F
    J Mol Diagn; 2018 Sep; 20(5):664-676. PubMed ID: 29959022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective evaluation of two screening methods for molecular testing of metastatic melanoma: Diagnostic performance of BRAF V600E immunohistochemistry and of a NRAS-BRAF fully automated real-time PCR-based assay.
    Vallée A; Denis-Musquer M; Herbreteau G; Théoleyre S; Bossard C; Denis MG
    PLoS One; 2019; 14(8):e0221123. PubMed ID: 31415669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRAF and NRAS mutations are heterogeneous and not mutually exclusive in nodular melanoma.
    Chiappetta C; Proietti I; Soccodato V; Puggioni C; Zaralli R; Pacini L; Porta N; Skroza N; Petrozza V; Potenza C; Della Rocca C; Di Cristofano C
    Appl Immunohistochem Mol Morphol; 2015 Mar; 23(3):172-7. PubMed ID: 24710085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance.
    Raaijmakers MI; Widmer DS; Narechania A; Eichhoff O; Freiberger SN; Wenzina J; Cheng PF; Mihic-Probst D; Desalle R; Dummer R; Levesque MP
    Oncotarget; 2016 Nov; 7(47):77163-77174. PubMed ID: 27791198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The BRAF and NRAS mutation prevalence in dermoscopic subtypes of acquired naevi reveals constitutive mitogen-activated protein kinase pathway activation.
    Tan JM; Tom LN; Jagirdar K; Lambie D; Schaider H; Sturm RA; Soyer HP; Stark MS
    Br J Dermatol; 2018 Jan; 178(1):191-197. PubMed ID: 28714107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.